New drug cocktail aims to shrink ovarian tumors before surgery

NCT ID NCT07407452

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enough to make surgery more effective. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iparomlimab and tuvonralimab (QL1706) combined with chemotherapy drugs (paclitaxel, carboplatin, cisplatin) or olaparib
What this could lead to
If successful, this could lead to a new treatment option before surgery for advanced ovarian cancer, potentially improving tumor shrinkage and surgical outcomes.
What could go wrong
This is an early Phase 2 trial with only 50 patients, so results may not apply to everyone. The combination of multiple drugs may cause significant side effects, and it is not yet known if it will improve long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.